AU2004230244B2 - S. pneumoniae antigens - Google Patents

S. pneumoniae antigens Download PDF

Info

Publication number
AU2004230244B2
AU2004230244B2 AU2004230244A AU2004230244A AU2004230244B2 AU 2004230244 B2 AU2004230244 B2 AU 2004230244B2 AU 2004230244 A AU2004230244 A AU 2004230244A AU 2004230244 A AU2004230244 A AU 2004230244A AU 2004230244 B2 AU2004230244 B2 AU 2004230244B2
Authority
AU
Australia
Prior art keywords
seq
pneumoniae
antibody
nucleic acid
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2004230244A
Other languages
English (en)
Other versions
AU2004230244A1 (en
Inventor
Shailesh Dewasthaly
Markus Hanner
Andreas Meinke
Eszter Nagy
Ulrike Stierschneider
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Valneva Austria GmbH
Original Assignee
Intercell Austria AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intercell Austria AG filed Critical Intercell Austria AG
Publication of AU2004230244A1 publication Critical patent/AU2004230244A1/en
Application granted granted Critical
Publication of AU2004230244B2 publication Critical patent/AU2004230244B2/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C07K14/3156—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci from Streptococcus pneumoniae (Pneumococcus)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6888—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms
    • C12Q1/689—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for detection or identification of organisms for bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2004230244A 2003-04-15 2004-04-15 S. pneumoniae antigens Ceased AU2004230244B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03450087.6 2003-04-15
EP03450087 2003-04-15
PCT/EP2004/003984 WO2004092209A2 (en) 2003-04-15 2004-04-15 S. pneumoniae antigens

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2011218655A Division AU2011218655A1 (en) 2003-04-15 2011-08-30 S. Pneumoniae Antigens

Publications (2)

Publication Number Publication Date
AU2004230244A1 AU2004230244A1 (en) 2004-10-28
AU2004230244B2 true AU2004230244B2 (en) 2011-09-22

Family

ID=33186037

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2004230244A Ceased AU2004230244B2 (en) 2003-04-15 2004-04-15 S. pneumoniae antigens

Country Status (7)

Country Link
US (3) US7635487B2 (cg-RX-API-DMAC7.html)
EP (11) EP2311987A1 (cg-RX-API-DMAC7.html)
JP (3) JP2007525157A (cg-RX-API-DMAC7.html)
CN (2) CN102174534A (cg-RX-API-DMAC7.html)
AU (1) AU2004230244B2 (cg-RX-API-DMAC7.html)
CA (1) CA2522238A1 (cg-RX-API-DMAC7.html)
WO (1) WO2004092209A2 (cg-RX-API-DMAC7.html)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6800744B1 (en) 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
US7128918B1 (en) * 1998-12-23 2006-10-31 Id Biomedical Corporation Streptococcus antigens
AU2002351623A1 (en) 2001-12-20 2003-07-09 Shire Biochem Inc. Streptococcus antigens
EP1694359A2 (en) * 2003-11-10 2006-08-30 UAB Research Foundation Compositions for reducing bacterial carriage and cns invasion and methods of using same
JP2010501012A (ja) * 2006-08-17 2010-01-14 ザ ユーエービー リサーチ ファウンデーション 免疫原性ＰｃｐＡポリペプチドおよびその使用
WO2008039838A2 (en) 2006-09-27 2008-04-03 St. Jude Children's Research Hospital Synthetic streptococcus pneumoniae vaccine
EP1923069A1 (en) 2006-11-20 2008-05-21 Intercell AG Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto
US8329195B2 (en) * 2007-05-23 2012-12-11 The Uab Research Foundation Detoxified pneumococcal neuraminidase and uses thereof
CN101848929A (zh) * 2007-05-25 2010-09-29 诺华有限公司 肺炎链球菌菌毛抗原
US20160228500A9 (en) * 2007-07-23 2016-08-11 Martina Ochs Immunogenic Polypeptides and Monoclonal Antibodies
CA2694466A1 (en) * 2007-07-23 2009-01-29 Sanofi Pasteur Limited Immunogenic polypeptides and monoclonal antibodies
GB0714963D0 (en) * 2007-08-01 2007-09-12 Novartis Ag Compositions comprising antigens
JP5697991B2 (ja) * 2008-02-01 2015-04-08 サノフィ パストゥール リミテッドＳａｎｏｆｉ Ｐａｓｔｅｕｒ Ｌｉｍｉｔｅｄ 診断的アッセイ
KR101208778B1 (ko) 2008-03-03 2012-12-05 노파르티스 아게 Ｔｌｒ 활성 조정제로서의 화합물 및 조성물
US8241643B2 (en) 2008-03-17 2012-08-14 Intercell Ag Peptides protective against S. pneumoniae and compositions, methods and uses relating thereto
EP2108656A1 (en) * 2008-03-19 2009-10-14 Beninati, Concetta Antigenic protein fragments of streptococcus pneumoniae
US11839430B2 (en) 2008-03-27 2023-12-12 Doheny Eye Institute Optical coherence tomography-based ophthalmic testing methods, devices and systems
US8348429B2 (en) 2008-03-27 2013-01-08 Doheny Eye Institute Optical coherence tomography device, method, and system
WO2009143483A2 (en) * 2008-05-22 2009-11-26 The Board Of Regents Of The University Of Texas System PsrP IS A PROTECTIVE ANTIGEN AGAINST PNEUMOCOCCAL INFECTION
EP3884844A1 (en) 2008-07-18 2021-09-29 Doheny Eye Institute Optical coherence tomography-based ophthalmic testing methods, devices and systems
ES2352704B1 (es) * 2008-08-08 2012-06-14 CONSEJO SUPERIOR DE INVESTIGACIONES CIENTÍFICAS (CSIC)(Titular al 80%) Secuencia de nucleotido y proteina b-galactosidasa de streptococcus mitis, procedimiento de obtencion y sus aplicaciones.
EP2327782B1 (en) * 2008-09-04 2015-02-25 Biotechnology Research Institute Chinese Academy of Agricultural Sciences Dna molecule for expressing haripin rna, the constructing method and the use thereof
WO2010029546A2 (en) * 2008-09-11 2010-03-18 Ben Gurion University Of The Negev Research And Development Authority Compositions and methods for treating s.pneumoniae infection
ATE523204T1 (de) 2009-02-16 2011-09-15 Karlsruher Inst Technologie Cd44v6-peptide als bakterielle infektionsinhibitoren
RU2555757C2 (ru) 2009-03-24 2015-07-10 Новартис Аг Комбинации менингококкового фактор н-связывающего белка и пневмококковых сахаридных конъюгатов
WO2010144734A1 (en) 2009-06-10 2010-12-16 Novartis Ag Benzonaphthyridine-containing vaccines
AU2010273708B2 (en) * 2009-06-29 2015-10-01 Children's Medical Center Corporation Vaccines and compositions against Streptococcus pneumoniae
CN102844047B (zh) 2009-09-02 2017-04-05 诺华股份有限公司 含tlr活性调节剂的免疫原性组合物
JO3257B1 (ar) 2009-09-02 2018-09-16 Novartis Ag مركبات وتركيبات كمعدلات لفاعلية tlr
BR112012008338A2 (pt) 2009-09-10 2019-09-24 Novartis Ag combinação de vacinas contra doenças do trato respiratório.
WO2011057148A1 (en) 2009-11-05 2011-05-12 Irm Llc Compounds and compositions as tlr-7 activity modulators
CN102762206A (zh) 2009-12-15 2012-10-31 诺华有限公司 免疫增强化合物的均匀悬液及其用途
US20130039947A1 (en) 2010-03-12 2013-02-14 Children's Medical Center Corporation Novel immunogens and methods for discovery and screening thereof
CA2792938C (en) 2010-03-23 2018-07-31 Irm Llc Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc.
WO2012072769A1 (en) 2010-12-01 2012-06-07 Novartis Ag Pneumococcal rrgb epitopes and clade combinations
JP6046632B2 (ja) 2010-12-03 2016-12-21 サノフィ パストゥール リミテッドＳａｎｏｆｉ Ｐａｓｔｅｕｒ Ｌｉｍｉｔｅｄ 肺炎球菌に対する免疫用組成物
MY163871A (en) 2011-01-20 2017-10-31 Genocea Biosciences Inc Vaccines and compositions against streptococcus pneumoniae
KR102084509B1 (ko) 2011-05-11 2020-03-05 칠드런'즈 메디컬 센터 코포레이션 변형 비오틴-결합 단백질, 그 융합 단백질 및 응용
CA2854934A1 (en) 2011-11-07 2013-05-16 Novartis Ag Carrier molecule comprising a spr0096 and a spr2021 antigen
WO2013124473A1 (en) * 2012-02-24 2013-08-29 Novartis Ag Pilus proteins and compositions
US20150132339A1 (en) 2012-03-07 2015-05-14 Novartis Ag Adjuvanted formulations of streptococcus pneumoniae antigens
BR112014029313A2 (pt) 2012-05-22 2017-06-27 Novartis Ag conjugado de meningococos do sorogrupo x
RU2510281C2 (ru) 2012-06-22 2014-03-27 Общество с ограниченной ответственностью "Эпитоп" (ООО "Эпитоп") ВАКЦИНА ПРОТИВ ПНЕВМОНИИ, ВЫЗЫВАЕМОЙ Streptococcus pneumoniae, НА ОСНОВЕ ГИБРИДНОГО БЕЛКА
WO2014018904A1 (en) * 2012-07-26 2014-01-30 Genocea Biosciences, Inc. Fused antigen vaccines and compositions against streptococcus pneumoniae
CN105188747A (zh) 2013-02-01 2015-12-23 葛兰素史密斯克莱生物公司 包含toll样受体激动剂的免疫组合物的皮内递送
WO2014124228A1 (en) 2013-02-07 2014-08-14 Children's Medical Center Corporation Protein antigens that provide protection against pneumococcal colonization and/or disease
US9226856B2 (en) 2013-03-14 2016-01-05 Envision Diagnostics, Inc. Inflatable medical interfaces and other medical devices, systems, and methods
WO2017048873A1 (en) 2015-09-17 2017-03-23 Envision Diagnostics, Inc. Medical interfaces and other medical devices, systems, and methods for performing eye exams
US10772497B2 (en) 2014-09-12 2020-09-15 Envision Diagnostics, Inc. Medical interfaces and other medical devices, systems, and methods for performing eye exams
EP3312287A4 (en) * 2015-06-18 2018-12-19 The Research Foundation for Microbial Diseases of Osaka University Method for measuring complement-dependent bactericidal function with respect to pneumococci
EP3448234A4 (en) 2016-04-30 2019-05-01 Envision Diagnostics, Inc. MEDICAL DEVICES, SYSTEMS AND METHODS FOR PERFORMING EYE EXAMINATIONS AND EYES TRACKING
US10738338B2 (en) 2016-10-18 2020-08-11 The Research Foundation for the State University Method and composition for biocatalytic protein-oligonucleotide conjugation and protein-oligonucleotide conjugate
US20200038499A1 (en) * 2017-03-22 2020-02-06 Modernatx, Inc. Rna bacterial vaccines
AU2018243910B2 (en) 2017-03-28 2025-04-10 The Children's Medical Center Corporation A multiple antigen presenting system (MAPS)-based staphylococcus aureus vaccine, immunogenic composition, and uses thereof
BR112019027387A8 (pt) 2017-06-23 2022-12-06 Univ Maryland Composições imunogênicas
DK3752182T3 (da) 2018-02-12 2024-08-12 Inimmune Corp Toll-like receptor ligands
GB201807380D0 (en) * 2018-05-04 2018-06-20 Karlsson Roger Biomarkers for detecting microbial infection
CN113164580B (zh) 2018-09-12 2025-06-10 儿童医疗中心公司 肺炎球菌融合蛋白疫苗
BR112021004193A2 (pt) 2018-09-12 2021-05-25 Affinivax, Inc. vacinas pneumocócicas multivalentes
RU2701733C1 (ru) * 2018-12-14 2019-10-01 Федеральное государственное бюджетное научное учреждение "Институт экспериментальной медицины" (ФГБНУ "ИЭМ") Живая вакцина на основе штамма пробиотиков ENTEROCOCCUS FAECIUM L3 для профилактики инфекции, вызванной STREPTOCOCCUS PNEUMONIE
CN111748535B (zh) * 2019-03-28 2022-07-05 安徽华恒生物科技股份有限公司 一种丙氨酸脱氢酶突变体及其在发酵生产l-丙氨酸中的应用
EP4240843A1 (en) 2020-11-04 2023-09-13 Eligo Bioscience Cutibacterium acnes recombinant phages, method of production and uses thereof
GB202100097D0 (en) * 2021-01-05 2021-02-17 Univ Liverpool Novel composition
CA3231684A1 (en) 2021-09-09 2023-03-16 Affinivax, Inc. Multivalent pneumococcal vaccines
EP4538370A1 (en) * 2022-06-07 2025-04-16 Peking University First Hospital Fusion protein containing truncated iga protease and use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001049721A2 (en) * 1999-12-30 2001-07-12 Bristol-Myers Squibb Company Bacterial genes and proteins that are essential for cell viability and their uses
WO2002077021A2 (en) * 2001-03-27 2002-10-03 Chiron Srl. Streptococcus pneumoniae proteins and nucleic acids

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US40000A (en) 1863-09-15 Improvement in sewing-machines
US4609231A (en) 1984-12-24 1986-09-02 Perfectdata Corporation Floppy diskette storage container
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
AU663053B2 (en) 1990-06-11 1995-09-28 Gilead Sciences, Inc. Nucleic acid ligands
DK0464533T3 (da) 1990-06-28 1999-04-26 Gen Hospital Corp Fusionsproteiner med immunglobulindele, deres fremstilling og anvendelse
ATE229543T1 (de) 1991-06-24 2002-12-15 Chiron Corp Polypeptide des hepatitis c-virus (hiv)
EP1167378B1 (en) 1994-07-15 2011-05-11 University of Iowa Research Foundation Immunomodulatory oligonucleotides
JPH11507214A (ja) * 1995-06-07 1999-06-29 バイオケム ヴァシーンズ インク． Ｈｓｐ７０ファミリーに属する連鎖球菌の熱ショック蛋白質メンバー
RS50101B (sr) 1996-02-24 2009-01-22 Boehringer Ingelheim International Gmbh., Farmaceutski preparati za imunomodulaciju
US6605713B1 (en) 1996-08-30 2003-08-12 Jens Peter Furste Mirror-symmetrical selection and evolution of nucleic acids
US5989912A (en) 1996-11-21 1999-11-23 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
US5849902A (en) 1996-09-26 1998-12-15 Oligos Etc. Inc. Three component chimeric antisense oligonucleotides
DE69739981D1 (de) * 1996-10-31 2010-10-14 Human Genome Sciences Inc Streptococcus pneumoniae-Antigene und Impfstoffe
WO1998019689A1 (en) * 1996-11-01 1998-05-14 Smithkline Beecham Corporation Novel coding sequences
US5981281A (en) * 1996-12-13 1999-11-09 Eli Lilly And Company Method for knockout mutagenesis in Streptococcus pneumoniae
US6800744B1 (en) * 1997-07-02 2004-10-05 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
DE19803453A1 (de) 1998-01-30 1999-08-12 Boehringer Ingelheim Int Vakzine
EP1144640A3 (en) * 1998-07-27 2001-11-28 Microbial Technics Limited Nucleic acids and proteins from streptococcus pneumoniae
WO2000006737A2 (en) * 1998-07-27 2000-02-10 Microbial Technics Limited Streptococcus pneumoniae proteins and nucleic acid molecules
US6951652B2 (en) * 1998-07-29 2005-10-04 Biosynth S.R.L. Vaccine for prevention of gram-negative bacterial infections and endotoxin related diseases
AU2027400A (en) * 1998-11-19 2000-06-05 St. Jude Children's Research Hospital Identification and characterization of novel pneumococcal choline binding proteins, cbpg and cbpd, and diagnostic and therapeutic uses thereof
NZ512574A (en) * 1998-12-23 2004-03-26 Iaf Biochem Int Novel streptococcus antigens useful as vaccines
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
AT409085B (de) 2000-01-28 2002-05-27 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung zur immunmodulation und herstellung von vakzinen
EP1272215B1 (en) 2000-04-14 2007-10-10 Intercell AG Pharmaceutical preparations comprising modified peptides
AT410173B (de) 2000-06-08 2003-02-25 Cistem Biotechnologies Gmbh Antigene zusammensetzung
IL152959A0 (en) 2000-06-08 2003-06-24 Intercell Biomedizinische Forschungs & Entwicklungs Gmbh Immunostimulatory oligodeoxynucleotides
AU2000279060A1 (en) 2000-07-10 2002-01-21 Telefonaktiebolaget Lm Ericsson (Publ) Resource management in uncoordinated frequency hopping system
CA2418854A1 (en) 2000-08-17 2002-02-21 Jorg Fritz A vaccine which comprises at least one antigen and a cathelididin derived antimicrobial peptide or a derivative thereof
AT410635B (de) 2000-10-18 2003-06-25 Cistem Biotechnologies Gmbh Vakzin-zusammensetzung
EP1328543B1 (en) 2000-10-27 2009-08-12 Novartis Vaccines and Diagnostics S.r.l. Nucleic acids and proteins from streptococcus groups a & b
AT410798B (de) 2001-01-26 2003-07-25 Cistem Biotechnologies Gmbh Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen
WO2002066650A2 (en) 2001-02-21 2002-08-29 Shire Biochem Inc. Streptococcus pyogenes polypeptides and corresponding dna fragments
AU2002306849A1 (en) * 2001-03-21 2002-10-08 Elitra Pharmaceuticals, Inc. Identification of essential genes in microorganisms
EP1421098A4 (en) 2001-04-13 2006-03-15 Wyeth Corp SURFACE PROTEINS OF STREPTOCOCCUS PYOGENES
EP2258842A1 (en) * 2001-04-16 2010-12-08 Wyeth Holdings Corporation Streptococcus pneumoniae open reading frames encoding polypeptide antigens and uses thereof
FR2824074A1 (fr) 2001-04-26 2002-10-31 Pasteur Institut Sequence du genome streptococcus agalactiae, application au developpement de vaccins, d'outils de diagnostic, et a l'identification de cibles therapeutiques
JP2005519035A (ja) 2001-12-07 2005-06-30 インターツェル・アクチェンゲゼルシャフト 免疫促進性オリゴデオキシヌクレオチド
GB0210128D0 (en) 2002-05-02 2002-06-12 Chiron Spa Nucleic acids and proteins from streptococcus groups A & B
JP4875490B2 (ja) 2003-07-31 2012-02-15 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド ＳｔｒｅｐｔｏｃｏｃｃｕｓＰｙｏｇｅｎｅｓについての免疫原組成物

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001049721A2 (en) * 1999-12-30 2001-07-12 Bristol-Myers Squibb Company Bacterial genes and proteins that are essential for cell viability and their uses
WO2002077021A2 (en) * 2001-03-27 2002-10-03 Chiron Srl. Streptococcus pneumoniae proteins and nucleic acids

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BETHE, G. et al., FEMS Microbiology Letters, 2001, vol. 205, pages 99-104 *
HOSKINS, J. et al., Journal of Bacteriology, 2001, vol. 183, pages 5709-5717 *
NABORS, G.S. et al., Vaccine, 2000, vol. 18, pages 1743-1754 *
OVERWEG, K. et al., Infection and Immunity, 2000, vol. 68, pages 4180-4188 *
TETTELIN, H. et al., Science, 2001, vol. 293, pages 498-506 *
WIZEMANN, T.M. et al., Infection and Immunity, 2001, vol. 69, pages 1593-1598 *

Also Published As

Publication number Publication date
EP2311987A1 (en) 2011-04-20
JP2007525157A (ja) 2007-09-06
CA2522238A1 (en) 2004-10-28
US20060263846A1 (en) 2006-11-23
EP1615950A2 (en) 2006-01-18
CN1774447B (zh) 2011-04-06
EP2311988A1 (en) 2011-04-20
EP2333114A1 (en) 2011-06-15
WO2004092209A3 (en) 2004-12-09
EP2336357A1 (en) 2011-06-22
EP2314718A1 (en) 2011-04-27
US20100260790A1 (en) 2010-10-14
WO2004092209A2 (en) 2004-10-28
HK1084958A1 (en) 2006-08-11
JP2011004753A (ja) 2011-01-13
EP2311989A1 (en) 2011-04-20
US7635487B2 (en) 2009-12-22
WO2004092209A9 (en) 2008-11-27
EP2311990A1 (en) 2011-04-20
EP2314719A1 (en) 2011-04-27
AU2004230244A1 (en) 2004-10-28
CN1774447A (zh) 2006-05-17
CN102174534A (zh) 2011-09-07
US20130136761A1 (en) 2013-05-30
US8372411B2 (en) 2013-02-12
EP2298934A1 (en) 2011-03-23
JP2012184236A (ja) 2012-09-27
EP2311991A1 (en) 2011-04-20

Similar Documents

Publication Publication Date Title
AU2004230244B2 (en) S. pneumoniae antigens
CA2413450C (en) Streptococcus antigens
US8431128B2 (en) Enterococcus antigens
JPH11513371A (ja) 肺炎球菌遺伝子、その一部、それ由来の発現産物、ならびに該遺伝子、該遺伝子の一部分、および該遺伝子産物の使用
IL137921A (en) Proteins and polypeptides of group B streptococcus
US20040096973A1 (en) Environmentally regulated genes of Streptococcus suis
US6764823B2 (en) Antimicrobial methods and materials
AU2011218655A1 (en) S. Pneumoniae Antigens
US20100221277A1 (en) Chlamydia pneumoniae antigens
HK1084958B (en) S. pneumoniae antigens
AU2011236092A1 (en) Enterococcus Antigens

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired